Salivary gland tumours are one of the most difficult areas of diagnostic pathology, with
significant morphological diversity and many overlapping features. The latest WHO …

Head and neck cancer (HNC) constitute 5% of all reported cancers. Among all, the oral
cavity cancer is the most frequent type of HNC which accounts for over half of HNC cases …

Background Larotrectinib is a first-in-class, highly selective, and central nervous system-
active tropomyosin receptor kinase (TRK) inhibitor approved for the treatment of adult and …

Malignant Salivary Gland Tumors - StatPearls - NCBI Bookshelf US flag An official website of
the United States government Here's how you know NIH NLM Logo Access keys NCBI …

Major salivary gland cancers (SGCs) comprise 5% of head and neck cancers in Europe. The
worldwide crude and ageadjusted incidence rates are 0.69 and 0.57 cases per 100000 …

The tyrosine receptor kinase (TRK) inhibitors larotrectinib and entrectinib were recently
approved in Canada for the treatment of solid tumours harbouring neurotrophic tyrosine …

Salivary gland malignancies are rare neoplasms that have a broad histological spectrum
and a variety of biologic behaviors. Salivary gland malignancies are known as chemo …

Salivary gland carcinomas (SGC) are a rare and variable group of head and neck cancers
with historically poor response to cytotoxic chemotherapy and immunotherapy in the …

Purpose The aim of this project was to provide an overview of the epidemiology of primary
salivary gland carcinomas (SGC) in terms of incidence, distribution of clinicopathological …

A recent discovery of revolutionary Clustered regularly interspaced palindromic repeats
(CRISPR) is a gene-editing tool that provides a type of adaptive immunity in prokaryotic …